Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Multimodality management of localized pancreatic cancer. Cancer J 2001;7 Suppl 1:S35-46

Date

08/16/2001

Pubmed ID

11504284

Scopus ID

2-s2.0-0006054476 (requires institutional sign-in at Scopus site)   14 Citations

Abstract

Despite improvements in surgical management, only a minority of patients enjoy long-term survival following pancreaticoduodenectomy for adenocarcinoma of the pancreas. Adjuvant therapy consisting of 5-fluorouracil and irradiation has improved median and 5-year survival rates; however, at least one third of eligible patients do not receive postoperative adjuvant therapy because of delayed recovery following pancreaticoduodenectomy. This has led to the development of treatment schedules incorporating the delivery of systemic therapy and/or chemoradiation prior to surgery. This article briefly outlines the history of adjuvant therapy for adenocarcinoma of the pancreas and reviews the available literature on neoadjuvant therapy for localized pancreatic cancer including investigational therapies under clinical trial evaluation.

Author List

Wayne JD, Wolff RA, Pisters PW, Evans DB

Author

Douglas B. Evans MD Professor in the Surgery department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adenocarcinoma
Antineoplastic Combined Chemotherapy Protocols
Chemotherapy, Adjuvant
Genetic Therapy
Humans
Neoadjuvant Therapy
Pancreatic Neoplasms
Pancreaticoduodenectomy
Preoperative Care
Radiotherapy, Adjuvant